Geen alternatieve tekst opgegeven voor deze afbeelding

This month is Multiple Myeloma Action Month! At Ingress-health we have an extensive experience in multiple myeloma, publishing manuscripts in many areas of the disease, including: the value of MRD-, comparative effectiveness of new agents, patient preferences, the impact of treatments on high risk cytogenetics and methodology to better predict survival of patients with multiple myeloma. As Ingress we are proud to be able to contribute to the body of evidence in multiple myeloma and this month we want to highlight some of our contributions. Check out the publications below for some of our work in multiple myeloma over time:

Nahi et al. 2016:

Dimopoulos et al. 2019:

Mateos et al. 2020: